Activities of Clinical Expertise and Research in a Rare Disease Referral Centre: A Place for Telemedicine beyond the COVID-19 Pandemic?

auto-immune diseases clinical research clinical trial rare diseases referral centre tele-expertise tele-trial teleconsultation telehealth telemedicine

Journal

Healthcare (Basel, Switzerland)
ISSN: 2227-9032
Titre abrégé: Healthcare (Basel)
Pays: Switzerland
ID NLM: 101666525

Informations de publication

Date de publication:
31 Aug 2023
Historique:
received: 12 08 2023
revised: 26 08 2023
accepted: 30 08 2023
medline: 9 9 2023
pubmed: 9 9 2023
entrez: 9 9 2023
Statut: epublish

Résumé

Rare disease referral centres are entrusted with missions of clinical expertise and research, two activities that have to contend with numerous obstacles. Providing specialist opinions is time-consuming, uncompensated and limited by difficulties in exchanging medical data. Clinical research is constrained by the need for frequent research protocol visits. Our objective was to determine whether telemedicine (TLM) can overcome these difficulties. To better characterise the activity of clinical expertise provided by our French centre, each opinion delivered by our team was reported on a standardised form. To investigate our clinical research activity, investigators and patients were asked to complete a questionnaire on the acceptability of research protocol teleconsultations. Regarding clinical expertise, our team delivered 120 opinions per week (representing a total of 21 h), of which 29% were delivered to patients and 69% to medical practitioners. If these were delivered using TLM, it would represent a potential weekly income of EUR 500 (tele-expertise) and EUR 775 (teleconsultations). Regarding the research activity, 70% of investigators considered the frequency of visits to be a limiting factor for patient inclusions; nearly half of the patients surveyed would be in favour of having teleconsultations in place of (40%) or in addition to (56%) in-person visits. Whereas TLM has become widely used as a back-up procedure to in-person consultations during the COVID-19 pandemic, the solutions it provides to the problems encountered in performing expertise and research activities have made it a new conventional follow-up modality for patients with rare diseases.

Identifiants

pubmed: 37685481
pii: healthcare11172447
doi: 10.3390/healthcare11172447
pmc: PMC10487162
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Clin Transl Sci. 2020 Sep;13(5):838-841
pubmed: 32526077
Orphanet J Rare Dis. 2021 Oct 29;16(1):454
pubmed: 34715889
Arthritis Care Res (Hoboken). 2017 Oct;69(10):1546-1557
pubmed: 27863164
Am J Med Genet A. 2019 Jun;179(6):885-892
pubmed: 30883013
Orphanet J Rare Dis. 2022 Sep 29;17(1):366
pubmed: 36175905
J Prev Alzheimers Dis. 2020;7(4):301-304
pubmed: 32920637
Eur J Cancer Care (Engl). 2018 Mar;27(2):e12587
pubmed: 27726212
Orphanet J Rare Dis. 2020 Jun 23;15(1):159
pubmed: 32576213
Rheumatology (Oxford). 2021 Jan 5;60(1):366-370
pubmed: 32893293
J Surg Oncol. 2021 Jan;123(1):359-360
pubmed: 33051875
Orphanet J Rare Dis. 2020 Jun 29;15(1):167
pubmed: 32600383
Soins Pediatr Pueric. 2013 Sep-Oct;(274):17-9
pubmed: 24228329
HSS J. 2020 Nov;16(Suppl 1):108-111
pubmed: 33041724
Telemed J E Health. 2020 Jul;26(7):912-919
pubmed: 31682204
Rev Med Interne. 2016 Aug;37(8):514-20
pubmed: 26681105
Cancer Treat Res Commun. 2016;9:139-142
pubmed: 28580436
Orphanet J Rare Dis. 2022 Dec 9;17(1):430
pubmed: 36494730
Orphanet J Rare Dis. 2020 Dec 3;15(1):341
pubmed: 33272301
J Telemed Telecare. 2022 Aug;28(7):508-516
pubmed: 32811275
Semin Arthritis Rheum. 2017 Aug;47(1):121-128
pubmed: 28420491
J Invest Dermatol. 2019 Aug;139(8):1626-1633.e1
pubmed: 31331443

Auteurs

Quentin Ducrocq (Q)

CHU Lille, Service de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), F-59000 Lille, France.

Laurence Guédon-Moreau (L)

Université de Lille, Faculté de Médecine et CHU de Lille, Clinique de Cardiologie et Maladies Vasculaires, F-59000 Lille, France.

David Launay (D)

CHU Lille, Service de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), F-59000 Lille, France.
Univ. Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, F-59000 Lille, France.
Inserm, F-59000 Lille, France.
Health Care Provider of the European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ReCONNET), F-59000 Lille, France.

Louis Terriou (L)

CHU Lille, Service de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), F-59000 Lille, France.

Sandrine Morell-Dubois (S)

CHU Lille, Service de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), F-59000 Lille, France.
Health Care Provider of the European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ReCONNET), F-59000 Lille, France.

Hélène Maillard (H)

CHU Lille, Service de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), F-59000 Lille, France.
Health Care Provider of the European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ReCONNET), F-59000 Lille, France.

Guillaume Lefèvre (G)

Univ. Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, F-59000 Lille, France.
Inserm, F-59000 Lille, France.
CHU Lille, Laboratoire d'Immunologie, F-59000 Lille, France.

Vincent Sobanski (V)

CHU Lille, Service de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), F-59000 Lille, France.
Univ. Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, F-59000 Lille, France.
Inserm, F-59000 Lille, France.
Health Care Provider of the European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ReCONNET), F-59000 Lille, France.

Marc Lambert (M)

CHU Lille, Service de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), F-59000 Lille, France.
Inserm, F-59000 Lille, France.
Health Care Provider of the European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ReCONNET), F-59000 Lille, France.
CHU Lille, Département de Médecine Polyvalente Post-Urgences, F-59000 Lille, France.
Univ. Lille, U1167-RIDAGE-Risk Factors and Molecular Determinants of Aging-Related Diseases, F-59000 Lille, France.

Cécile Yelnik (C)

CHU Lille, Service de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), F-59000 Lille, France.
Inserm, F-59000 Lille, France.
Health Care Provider of the European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ReCONNET), F-59000 Lille, France.
CHU Lille, Département de Médecine Polyvalente Post-Urgences, F-59000 Lille, France.
Univ. Lille, U1167-RIDAGE-Risk Factors and Molecular Determinants of Aging-Related Diseases, F-59000 Lille, France.

Meryem-Maud Farhat (MM)

CHU Lille, Service de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), F-59000 Lille, France.
Health Care Provider of the European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ReCONNET), F-59000 Lille, France.

Maria José Garcia Fernandez (MJ)

Unité Matériaux et Transformations (UMET) UMR CNRS 8207, Université Lille 1, F-59655 Villeneuve d'Ascq, France.
Inserm, CHU Lille, U1008-Controlled Drug Delivery System and Biomaterials, University Lille, F-59000 Lille, France.

Eric Hachulla (E)

CHU Lille, Service de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), F-59000 Lille, France.
Univ. Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, F-59000 Lille, France.
Inserm, F-59000 Lille, France.
Health Care Provider of the European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ReCONNET), F-59000 Lille, France.

Sébastien Sanges (S)

CHU Lille, Service de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), F-59000 Lille, France.
Univ. Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, F-59000 Lille, France.
Inserm, F-59000 Lille, France.
Health Care Provider of the European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ReCONNET), F-59000 Lille, France.

Classifications MeSH